Higher leuprolide dose does not diminish the ovarian response to gonadotropins in a protocol using pre-treatment with oral contraceptives

2009 ◽  
Vol 108 (1) ◽  
pp. 69-70
Author(s):  
Bradley S. Hurst ◽  
Kelly M. Hurst ◽  
Michelle L. Matthews
Author(s):  
E. Scott Sills ◽  
E. Scott Sills ◽  
J. L. Petersen ◽  
N. S. Rickers ◽  
Samuel H. Wood ◽  
...  

This registered, prospective clinical trial assessed serum anti-Mullerian hormone (AMH) patterns after treatment with activated platelet rich plasma (PRP). Patients with low ovarian reserve and/or at least 1 prior failed in vitro fertilization (IVF) cycle (n=182) received PRP injected into ovarian tissue under ultrasound guidance. Pretreatment AMH, BMI and platelet (PLT) concentration were recorded and serum AMH, follicle stimulating hormone, and estradiol were then measured at 2-week intervals for up to three months. Mean±SD patient age was 45.4±6.1yrs. Improved serum AMH was observed in 51 patients (28%) with median increase of 167% [95%CI 91; 280] after treatment; mean interval to maximum AMH increase was 4 weeks (range 2-10 weeks). Improved post-treatment AMH was not limited to younger patients; when stratified by age (<42 vs. ≥42yrs), significant AMH improvements were seen in both groups after treatment (p=0.03 and 0.009, respectively). Among responders, mean basal PLT count was higher (274K) vs. non-responders (250K); p<0.001. This is the first clinical trial to describe an intraovarian PRP technique for low reserve and finds the treatment safe and associated with significant increases in serum AMH for some patients, usually within four weeks. The substantially different pre-treatment PLT concentrations measured across PRP response groups warrants further investigation. Additional research can characterize ovarian response better, optimize PRP protocols, and collect outcomes data from those who subsequently undergo IVF with autologous oocytes.


2009 ◽  
Vol 54 (No. 11) ◽  
pp. 507-516 ◽  
Author(s):  
A. Marton ◽  
V. Faigl ◽  
M. Kerestes ◽  
M. Kulcsar ◽  
S. Nagy ◽  
...  

The ovarian response to a standard chronogest + eCG treatment with plasma levels of insulin, insulin-like growth factor-I (IGF-I), thyroids, non-esterified fatty acids (NEFA), OH-butyrate (BHB) and urea-N (PUN) was studied in lactating Awassi ewes (<i>n</i> = 105) during the late-summer – early autumn transition period. The ewes were inseminated with diluted fresh semen after gestagen removal, and mated thereafter; 26 of them conceived at the fixed-time AI (fix AI; conception rate is calculated from lambing dates). Ovarian function was monitored by milk progesterone (P<sub>4</sub>) profiles. Before synchronization, the ovary was still acyclic in 33 and already cyclic in 72 ewes. Twenty-nine and 43 of the cyclic animals were in the follicular and luteal phases, respectively. After gestagen removal almost all (<i>n</i> = 104) ewes ovulated, although at AI elevated P<sub>4</sub> levels related to the presence of partially luteinized follicles, and short-lived CL-s were observed in 10 and five animals (none of them re-conceived at the fixed time AI). Cycling ewes showed higher insulin and IGF-I levels than the acyclic animals, and those who had not conceived had higher PUN than the pregnant ones. The other metabolic parameters did not differ. Neither conception rate, nor the ovarian response was influenced by the pre-treatment.


1971 ◽  
Vol 68 (2) ◽  
pp. 271-284 ◽  
Author(s):  
W. P. Collins ◽  
E. N. Koullapis ◽  
I. F. Sommerville

ABSTRACT The effect of chlormadinone acetate (6-chloro-17α-hydroxypregna-4,6-diene-3,20-dione-17-acetate) on the secretion and metabolism of progesterone has been investigated in six healthy women. Twenty-four hour urine samples were collected daily throughout pre-treatment cycles and again throughout the second cycle of treatment with 0.5 mg/day chlormadinone acetate. In all urine specimens LH, pregnanediol, oestrone, 17β-oestradiol, and oestriol were determined. Progesterone metabolism was assessed in terms of the transformation of labelled progesterone administered intravenously nine days after the urinary LH peak and progesterone production was calculated from the conversion of labelled hormone to urinary 5β-pregnane-3α,20α-diol glucuroniside and the mass of urinary metabolite of endogenous origin. The results suggested that although the LH peak was markedly suppressed in all subjects (P 0.05 – 0.02; t test), the ovarian response could be divided into two categories. In three individuals, a low but definite premenstrual rise in LH excretion persisted and this was associated with normal or only moderately suppressed progesterone production rates. In addition, there was only a minimal decrease in the level of pregnanediol during the luteal phase of the cycle and in the cyclical excretion of urinary oestrogens. These results are consistent with the luteinisation of a developing follicle without ovulation having necessarily occurred. In the remaining three subjects, the premenstrual rise in LH was not detectable and progesterone production was markedly suppressed. There was no evidence of a rise in pregnanediol in the second half of the cycle in two patients and in the third the level was markedly reduced. In addition, in two of those cycles there was suppression of urinary oestrogen excretion. In treated cycles, there was a significantly lower incorporation of radioactivity into products liberated by solvolysis (P 0.02–0.01; t test). Furthermore, in subjects in whom the progesterone production rate was not markedly suppressed, there was a significant decrease in the conversion of administered progesterone to 5β-pregnane-3α,20α-diol (P 0.01–0.001; t test) and some increase in the conversion to 5α-pregnan-3α-ol-20-one (P 0.02–0.01;t test).


Sign in / Sign up

Export Citation Format

Share Document